Table 2.
Demographic and clinical characteristics of subjects with NASH in cohort 2
| CONTROL | NASH | P-value | |
|---|---|---|---|
| DEMOGRAPHICS | |||
| N | 31 | 31 | -- |
| Age (years) | 25.7± 4.7 | 53.5±10.2 | <.0001 |
| BMI (kg/m2) | 34.0±4.0 | 35.6±7.6 | 0.286 |
| Caucasian (%) | 47 | 90 | -- |
| Black (%) | 53 | 10 | -- |
| LABORATORY | |||
| Alanine Aminotransferase (IU/L) | 16.8±3.8 | 94.7±67.6 | <.0001 |
| Aspartate Aminotransferase (IU/L) | 23.1±7.3 | 46.7±24.1 | <.0001 |
| Alkaline Phosphatase | 70.6±16.3 | 102.4±31.2 | <.0001 |
| Glucose (mg/dL) | 84.3±7.1 | 86.6±17.2 | 0.474 |
| Insulin (uU/L) | 6.34±4.13 | 21.12±14.86 | <.0001 |
| Liver Fat Score | −3.099±0.783 | -- | -- |
| HISTOLOGY | |||
| Steatosis | |||
| Less than 5% | -- | 0 | |
| 5–33% | -- | 25.8% | |
| 33–66% | -- | 58.1% | |
| More than 67% | -- | 16.1% | |
| Lobular Inflammation | |||
| None | -- | 0 | |
| Less than 2×/hpf | -- | 58.1% | |
| Between 2–4×/hpf | -- | 38.7% | |
| More than 4×/hpf | -- | 3.2% | |
| Cytologic Ballooning | |||
| None | -- | 6.5% | |
| Few | -- | 35.5% | |
| Many | -- | 58.1% | |
| Fibrosis | |||
| None | -- | 9.7% | |
| Stage 1 | -- | 35.5% | |
| Stage 2 | -- | 22.6% | |
| Stage 3 | -- | 32.3% | |
| Stage 4 | -- | 0% | |